(via NewsDirect)
TNX 102 SL, Tonix's drug candidate, demonstrated remarkable efficacy in the second phase three clinical trial. The primary pain endpoint achieved an exceptionally low p-value of 0.00005. What's even more promising is that TNX 102 SL is a non-opioid medication with no recognized addictive potential.
In addition to addressing pain, the drug also effectively tackled other Fibromyalgia symptoms such as fatigue and sleep disturbances. Lederman informed Proactive that the company's next steps involve filing a new drug application (NDA) for FDA approval. They anticipate a pre-NDA meeting scheduled for the first half of 2024.
This groundbreaking development places
Contact Details
+1 604-688-8158
na-editorial@proactiveinvestors.com
Copyright (c) 2024 TheNewswire - All rights reserved.
Copyright (c) 2024 TheNewswire - All rights reserved., source